Viewing Study NCT00486252



Ignite Creation Date: 2024-05-05 @ 5:33 PM
Last Modification Date: 2024-10-26 @ 9:33 AM
Study NCT ID: NCT00486252
Status: COMPLETED
Last Update Posted: 2021-03-01
First Post: 2007-06-12

Brief Title: Non Interventional Study in Patients With Open Angle Glaucoma andor Ocular Hypertension Treated With XALATAN
Sponsor: Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization: Pfizer

Study Overview

Official Title: Non Interventional Study in Patients With Open Angle Glaucoma andor Ocular Hypertension Treated With XALATAN Latanoprost as First-Line Monotherapy and as Second-Line Monotherapy After Beta-Blockers Therapy Failure
Status: COMPLETED
Status Verified Date: 2009-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The primary objective is to evaluate the Intraocular pressure reducing effect of Xalatan over 3 months The secondary objective is to study the other efficacy parameters during treatment for 3 months
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None